- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00589550
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
A Phase I Study Of Peginterferon Alfa-2b (PEG-INTRON) With Sorafenib (Nexavar) In Patients With Unresectable Or Metastatic Clear Cell Renal Carcinoma (RCC).
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stop the growth of kidney cancer by blocking blood flow to the tumor. Giving PEG-interferon alfa-2b together with sorafenib may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of PEG-interferon alfa-2b and sorafenib in treating patients with unresectable or metastatic kidney cancer.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
Primary
- To determine the maximum tolerated dose and toxicity of PEG-interferon alfa-2b and sorafenib tosylate in patients with unresectable or metastatic clear cell renal cell carcinoma.
Secondary
- To determine the progression-free survival of patients treated with this regimen.
- To evaluate, in a preliminary manner, the response rate and overall survival of patients treated with this regimen.
- To evaluate the activation of interferon-induced transcription factors in immune cell subsets (including regulatory T cells [T regs]) using a novel flow cytometric assay and correlate this information with clinical outcome.
- To measure circulating levels of IFN-γ and IL-5 for determination of Th1/Th2 status and CD4+, CD25+, and FoxP3 cell number (T regs) in peripheral blood.
OUTLINE: Patients receive PEG-interferon alfa-2b subcutaneously on days 1, 8, 15, 22, 29, 36, 43, and 50. Patients also receive oral sorafenib tosylate 2-3 times daily on days 15-56 of course 1 and on days 1-56 of all subsequent courses. Courses repeat every 56 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
Blood samples are collected at baseline and periodically during study for correlative laboratory studies. Peripheral blood mononuclear cells are analyzed for STAT proteins (STAT1, STAT2, STAT3, STAT4, STAT5) and CD4+, CD25+, and FoxP3 regulatory T cells by flow cytometric assays. Samples are also analyzed for the presence of VEGF, VEGFR, IFN-γ, and IL-5 by ELISA assays; baseline expression of Jak-STAT signaling intermediates (Jak1, Tyk2, IFNAR, and IRF9) by immunoblot analysis; and interferon-stimulated gene expression by real time PCR and RT-PCR analysis.
After completion of study therapy, patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Must have histologically or cytologically confirmed clear cell renal cell carcinoma (RCC)
- Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension and is ≥ 1.0 cm by spiral CT scan
- No prior treatment except
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Life expectancy > 6 months
- Good/intermediate Motzer prognostic status
- ANC ≥ 1,000/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 10.0 g/dL
- Total bilirubin ≤ 2.0 mg/dL
- AST and ALT < 2.5 times normal
- Creatinine ≤ 1.8 mg/dL OR creatinine clearance > 50 mL/min
- Calcium < 12 mg/dL (when corrected for serum albumin)
- INR < 1.5 times upper limit of normal
- Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40% by 2D echo
- Pulse oximetry ≥ 90% at rest on room air
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
- No evidence of bleeding diathesis
- No uncontrolled coagulation disorders
- No active infections requiring IV antibiotics
- No known HIV, hepatitis C, or hepatitis B
- No autoimmune disease requiring ongoing therapy
- No requirement for adrenal replacement
- No angina (controlled or uncontrolled)
- No uncontrolled hypertension
No history of other major medical illnesses including, but not limited to, any of the following:
- Cardiac ischemia
- Myocardial infarction
- Major cardiac arrhythmias
- Inflammatory bowel disorders
- No other prior malignancy except for previously treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 3 years
- No significant psychiatric disease that, in the opinion of the principal investigator, would preclude giving adequate informed consent or render immunotherapy unsafe
PRIOR CONCURRENT THERAPY:
No prior treatment for RCC except sunitinib malate
- Patients may have progressed or have been intolerant to sunitinib malate
- No prior systemic treatment for metastatic disease (other than sunitinib malate)
- No prior organ allografts
- At least 2 weeks since prior laparoscopic/robotic surgery
- At least 4 weeks since prior open nephrectomy
- More than 4 weeks since prior and no concurrent radiotherapy or other surgery
- More than 4 weeks since prior systemic steroids
- More than 2 weeks since prior topical, injected, or inhaled steroids
- No concurrent steroid therapy
- No concurrent Hypericum perforatum (St. John's wort)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Peginterferon alfa-2b
Peginterferon alfa-2b will be administered SC on day 1 of each week of therapy.
This will most likely be a Monday or a Tuesday.
Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
|
Andere Namen:
administered SC on day 1 of each week of therapy.
This will most likely be a Monday or a Tuesday.
Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Maximum Tolerated Dose of PEG-interferon Alfa-2b and Sorafenib Tosylate
Zeitfenster: up to 2 months
|
up to 2 months
|
Characterize the Toxicity of Peginterferon Alfa-2b and Sorafenib in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma.
Zeitfenster: up to 2 months
|
up to 2 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Progression-free Survival of Patients Receiving Peginterferon Alfa-2b and Sorafenib.
Zeitfenster: up to 1 year
|
up to 1 year
|
Response Rate of Patients Receiving Peginterferon Alfa-2b and Sorafenib.
Zeitfenster: up to 1 year
|
up to 1 year
|
Overall Survival
Zeitfenster: up to 1 year
|
up to 1 year
|
Activation of Interferon-induced Transcription Factors in Immune Cell Subsets by Flow Cytometry and Correlation of This Information With Clinical Outcome
Zeitfenster: up to 1 year
|
up to 1 year
|
Circulating Levels of IFN-γ and IL-5 for Determination of Th1/Th2 Status and CD4+, CD25+, and FoxP3 Cell Number (T Regs) in Peripheral Blood
Zeitfenster: Up to 1 year
|
Up to 1 year
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienstuhl: Thomas E. Olencki, DO, Ohio State University Comprehensive Cancer Center
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach histologischem Typ
- Neubildungen
- Urologische Neubildungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Nierenerkrankungen
- Urologische Erkrankungen
- Adenokarzinom
- Karzinom
- Neubildungen, Drüsen und Epithelien
- Nierentumoren
- Karzinom, Nierenzelle
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Enzym-Inhibitoren
- Antineoplastische Mittel
- Immunologische Faktoren
- Proteinkinase-Inhibitoren
- Interferone
- Interferon-alpha
- Sorafenib
- Interferon alpha-2
- Peginterferon alfa-2b
Andere Studien-ID-Nummern
- OSU-06113
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Genexpressionsanalyse
-
Vanderbilt University Medical Center4DMedicalAbgeschlossen
-
Public Health EnglandCardiff University; Aneurin Bevan University Health BoardUnbekanntLungenentzündung | Sepsis | Herzstillstand | DAMEN UND HERREN | Bauch SepsisVereinigtes Königreich
-
Tatarstan Cancer CenterUnbekanntErblicher BrustkrebsRussische Föderation
-
Amina Fouad FaragAbgeschlossenKarzinom Ex Pleomorphes Adenom der Speicheldrüsen | Pleomorphes Adenom der SpeicheldrüsenÄgypten
-
Second Affiliated Hospital, School of Medicine,...First People's Hospital of HangzhouRekrutierungAkuter Myokardinfarkt | PD1China
-
Samsung Medical CenterRekrutierungDreifach negativer Brustkrebs | Immun-Checkpoint-InhibitorKorea, Republik von
-
Asociación Científica Latina A.C.Universidad Autonoma del Estado de MexicoAbgeschlossenRheumatoide Arthritis
-
Pusan National University HospitalAbgeschlossen
-
Imperial College LondonNoch keine RekrutierungEierstocktumoren | Eierstockkrebs | Eierstockkrebs | Keimzelltumor | Eierstock Neoplasma | Keimzellkrebs | Keimzell-Eierstockkrebs | Keimzellneoplasie
-
Beijing 302 HospitalRekrutierung